Life Sciences

Catalent Publishes Second Annual Corporate Responsibility Report Highlighting Achievements in an Extraordinary Year for the Pharmaceutical Industry

Catalent, Inc., the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene and therapies, and consumer health products, today published its Corporate Responsibility (CR) Report for fiscal year 2020. The report covers environmental, social, and governance (ESG) topics relevant to Catalent’s business, charting the company’s performance against the Sustainability Accounting Standards Board (SASB) standard for the biotechnology and pharmaceutical industries.

Building on the foundation laid with Catalent’s first CR report in 2020 (covering fiscal 2019), which set out goals in areas such as energy efficiency, diversity and inclusion, and community investment, this new report highlights the progress made in a year when the company, and the biotechnology and pharmaceutical industries in general, focused on responding to the global COVID-19 pandemic.

“Our 2020 fiscal year was an extraordinarily challenging period for everyone, but it allowed us to demonstrate the importance of our corporate responsibility commitment. At the heart of this commitment is Catalent’s “Patient First” philosophy, which has been fundamental to our work developing and manufacturing so many COVID-19 vaccines and treatments for customers as part of the fight against the worldwide pandemic,” commented John Chiminski, Chair and Chief Executive Officer of Catalent. He added, “I am incredibly proud that, throughout these most challenging of times, we have continued to prioritize the needs of people and patients, in line with our values and culture. This, our second corporate responsibility report, continues to formalize our progress in this area, supporting Catalent’s aim to be the world’s most trusted, reliable, and innovative drug development partner.”

Highlights of the report include wider sustainability commitments that now include water-efficiency and waste-reduction targets, and a goal for all sites to discharge wastewater with API concentrations below Predicted No-Effect Concentration (PNEC) levels by fiscal 2024. Additionally, 50 projects focusing on energy efficiency at Catalent’s global facilities were completed through the end of the 2020 fiscal year, with six Catalent sites transitioning to 100 percent renewable electricity sources. In fiscal 2020, the company also developed a human rights statement and expanded its diverse recruiting and talent development partnerships. It also established a well-being forum and adapted how it communicates with its employees, adopted more flexible work practices, and increased mental health and family initiatives, in part to account for the effects of the COVID-19 pandemic on its workforce. The “Catalent Cares” community giving and volunteer program that was launched in fiscal 2018 to strengthen employees’ ability to give back to society has seen 500 non-profit organizations benefit in fiscal 2020, alongside a number of COVID-19 grants made to communities in need.